{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:02:14Z","timestamp":1793055734488,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40123-026-01348-7","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:10:26Z","timestamp":1773429026000},"page":"1313-1340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunomodulation of the Ocular Surface in Severe Dry Eye Disease: Expert-Driven Literature Review on Treatment Strategies with Description of Representative Challenging Cases"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0289","authenticated-orcid":false,"given":"Giuseppe","family":"Giannaccare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botagoz","family":"Issergepova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Tak\u00e1\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Wr\u00f3bel-Dudzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnara","family":"Begimbayeva Yenbekovna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia Margareta","family":"Bogdanici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Deryapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Ku\u0161ev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Stawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luidmila","family":"Troychenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rejdak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Chor\u0105giewicz.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1348_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","volume":"15","author":"C Belmonte","year":"2017","unstructured":"Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15:404\u201337.","journal-title":"Ocul Surf"},{"key":"1348_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276\u201383. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008.","journal-title":"Ocul Surf"},{"key":"1348_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61030460","volume":"61","author":"J Kwon","year":"2025","unstructured":"Kwon J, Moghtader A, Kang C, Bibak Bejandi Z, Shahjahan S, Alzein A, et al. Overview of dry eye disease for primary care physicians. Medicina. 2025;61:460.","journal-title":"Medicina"},{"key":"1348_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334\u201365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003.","journal-title":"Ocul Surf"},{"key":"1348_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","volume":"157","author":"AJ Paulsen","year":"2014","unstructured":"Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, et al. Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157:799\u2013806. https:\/\/doi.org\/10.1016\/j.ajo.2013.12.023.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7150\/ijms.17718","volume":"14","author":"T Both","year":"2017","unstructured":"Both T, Dalm VA, van Hagen PM, van Daele PL. Reviewing primary Sj\u00f6gren\u2019s syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14:191\u2013200. https:\/\/doi.org\/10.7150\/ijms.17718.","journal-title":"Int J Med Sci"},{"key":"1348_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.31138\/mjr.29.3.127","volume":"29","author":"S Ziaragkali","year":"2018","unstructured":"Ziaragkali S, Kotsalidou A, Trakos N. Dry eye disease in routine rheumatology practice. Mediterr J Rheumatol. 2018;29:127\u201339. https:\/\/doi.org\/10.31138\/mjr.29.3.127.","journal-title":"Mediterr J Rheumatol"},{"key":"1348_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","volume":"15","author":"JAP Gomes","year":"2017","unstructured":"Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, et al. Tfos dews ii iatrogenic report. Ocul Surf. 2017;15:511\u201338.","journal-title":"Ocul Surf"},{"key":"1348_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2211-5056.369606","volume":"13","author":"A Nguyen","year":"2023","unstructured":"Nguyen A, Kolluru A, Beglarian T. Dry eye disease: a review of anti-inflammatory therapies. Taiwan J Ophthalmol. 2023;13:3\u201312. https:\/\/doi.org\/10.4103\/2211-5056.369606.","journal-title":"Taiwan J Ophthalmol"},{"key":"1348_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/opth.S184412","volume":"13","author":"RC de Oliveira","year":"2019","unstructured":"de Oliveira RC, Wilson SE. <article-title update=\"added\"><p>Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease<\/p>. Clin Ophthalmol. 2019;13:1115\u201322. https:\/\/doi.org\/10.2147\/opth.S184412.","journal-title":"Clin Ophthalmol"},{"key":"1348_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.033","author":"JS Wolffsohn","year":"2025","unstructured":"Wolffsohn JS, Ben\u00edtez-Del-Castillo J, Loya-Garcia D, Inomata T, Iyar G, Liang L, et al. TFOS DEWS III diagnostic methodology. Am J Ophthalmol. 2025. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.033.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/eye.2014.38","volume":"28","author":"X Tan","year":"2014","unstructured":"Tan X, Sun S, Liu Y, Zhu T, Wang K, Ren T, et al. Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome. Eye Lond. 2014;28:608\u201313. https:\/\/doi.org\/10.1038\/eye.2014.38.","journal-title":"Eye Lond"},{"key":"1348_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","volume":"15","author":"C Belmonte","year":"2017","unstructured":"Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15:404\u201337. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.002.","journal-title":"Ocul Surf"},{"key":"1348_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438\u2013510. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.011.","journal-title":"Ocul Surf"},{"key":"1348_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","volume":"118","author":"KS Kunert","year":"2000","unstructured":"Kunert KS, Tisdale AS, Stern ME, Smith J, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489\u201396.","journal-title":"Arch Ophthalmol"},{"key":"1348_CR16","unstructured":"Golden MI, Meyer JJ, Zeppieri M, et al. Dry Eye Syndrome. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470411\/."},{"key":"1348_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15633-1","volume":"15","author":"F Lixi","year":"2025","unstructured":"Lixi F, Coco G, Corda C, Villani E, Curci A, Slidsborg C, et al. Light discomfort thresholds under different lighting conditions in healthy subjects and dry eye patients. Sci Rep. 2025;15:29213. https:\/\/doi.org\/10.1038\/s41598-025-15633-1.","journal-title":"Sci Rep"},{"key":"1348_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/aos.12012","volume":"92","author":"BD Sullivan","year":"2014","unstructured":"Sullivan BD, Crews LA, Messmer EM, Foulks GN, Nichols KK, Baenninger P, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol. 2014;92:161\u20136. https:\/\/doi.org\/10.1111\/aos.12012.","journal-title":"Acta Ophthalmol"},{"key":"1348_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1167\/iovs.03-0915","volume":"46","author":"P Mertzanis","year":"2005","unstructured":"Mertzanis P, Abetz L, Rajagopalan K, Espindle D, Chalmers R, Snyder C, et al. The relative burden of dry eye in patients\u2019 lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci. 2005;46:46\u201350. https:\/\/doi.org\/10.1167\/iovs.03-0915.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1348_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep22480","volume":"6","author":"M Ayaki","year":"2016","unstructured":"Ayaki M, Kawashima M, Negishi K, Kishimoto T, Mimura M, Tsubota K. Sleep and mood disorders in dry eye disease and allied irritating ocular diseases. Sci Rep. 2016;6:22480. https:\/\/doi.org\/10.1038\/srep22480.","journal-title":"Sci Rep"},{"key":"1348_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15:575\u2013628. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006.","journal-title":"Ocul Surf"},{"key":"1348_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015070.pub2","author":"SH Liu","year":"2022","unstructured":"Liu SH, Saldanha IJ, Abraham AG, Rittiphairoj T, Hauswirth S, Gregory D, et al. Topical corticosteroids for dry eye. Cochrane Database Syst Rev. 2022. https:\/\/doi.org\/10.1002\/14651858.CD015070.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1348_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. Tfos dews ii pathophysiology report. Ocul Surf. 2017;15:438\u2013510.","journal-title":"Ocul Surf"},{"key":"1348_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jtos.2013.07.003","volume":"11","author":"C Baudouin","year":"2013","unstructured":"Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246\u201358. https:\/\/doi.org\/10.1016\/j.jtos.2013.07.003.","journal-title":"Ocul Surf"},{"key":"1348_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/life12111932","volume":"12","author":"J Prinz","year":"2022","unstructured":"Prinz J, Maffulli N, Fuest M, Walter P, Bell A, Migliorini F. Efficacy of topical administration of corticosteroids for the management of dry eye disease: systematic review and meta-analysis. Life. 2022;12:1932.","journal-title":"Life"},{"key":"1348_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.010","volume":"124","author":"SC Pflugfelder","year":"2017","unstructured":"Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124:S4-s13. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.010.","journal-title":"Ophthalmology"},{"key":"1348_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","volume":"130","author":"W Stevenson","year":"2012","unstructured":"Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90\u2013100.","journal-title":"Arch Ophthalmol"},{"key":"1348_CR28","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S300047","author":"KJ Ryu","year":"2021","unstructured":"Ryu KJ, Kim S, Kim MK, Paik HJ, Kim DH. Short-term therapeutic effects of topical corticosteroids on refractory dry eye disease: clinical usefulness of matrix metalloproteinase 9 testing as a response prediction marker. Clin Ophthalmol. 2021. https:\/\/doi.org\/10.2147\/OPTH.S300047.","journal-title":"Clin Ophthalmol"},{"key":"1348_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2024.1449283","author":"D Huang","year":"2024","unstructured":"Huang D, Li Z. Multidimensional immunotherapy for dry eye disease: current status and future directions. Front Ophthalmol. 2024. https:\/\/doi.org\/10.3389\/fopht.2024.1449283.","journal-title":"Front Ophthalmol"},{"key":"1348_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40135-020-00249-7","volume":"8","author":"H Favre","year":"2020","unstructured":"Favre H, Lahoti S, Issa N, Johnson DA, Kheirkhah A. Topical steroids in management of dry eye disease. Curr Ophthalmol Rep. 2020;8:195\u2013200. https:\/\/doi.org\/10.1007\/s40135-020-00249-7.","journal-title":"Curr Ophthalmol Rep"},{"key":"1348_CR31","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs. N Engl J Med. 2005;353:1711\u201323.","journal-title":"N Engl J Med"},{"key":"1348_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.exer.2006.02.004","volume":"83","author":"CS De Paiva","year":"2006","unstructured":"De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li D-Q, Stern ME, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526\u201335.","journal-title":"Exp Eye Res"},{"key":"1348_CR33","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1167\/iovs.05-1281","volume":"47","author":"CS De Paiva","year":"2006","unstructured":"De Paiva CS, Corrales RM, Villarreal AL, Farley W, Li D-Q, Stern ME, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47:2847\u201356.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1348_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/01.ico.0000240079.24583.a1","volume":"26","author":"K Lekhanont","year":"2007","unstructured":"Lekhanont K, Leyngold IM, Suwan-Apichon O, Rangsin R, Chuck RS. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea. 2007;26:84\u20139.","journal-title":"Cornea"},{"key":"1348_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","volume":"121","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Torkildsen GL, Lonsdale JD, D\u2019Ambrosio FA Jr, McLaurin EB, Eiferman RA, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121:475\u201383.","journal-title":"Ophthalmology"},{"key":"1348_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/ICO.0b013e31818c69ef","volume":"31","author":"Y-j Byun","year":"2012","unstructured":"Byun Y-j, Kim T-i, Kwon SM, Seo KY, Kim SW, Kim EK, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2012;31:509\u201313.","journal-title":"Cornea"},{"key":"1348_CR37","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.3390\/ijms25105479","volume":"25","author":"\u0141 Drzyzga","year":"2024","unstructured":"Drzyzga \u0141, \u015apiewak D, Dorecka M, Wygl\u0119dowska-Promie\u0144ska D. Available therapeutic options for corneal neovascularization: a review. Int J Mol Sci. 2024;25:5479.","journal-title":"Int J Mol Sci"},{"key":"1348_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/789623","volume":"2012","author":"TL Comstock","year":"2012","unstructured":"Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623. https:\/\/doi.org\/10.1155\/2012\/789623.","journal-title":"Int J Inflam"},{"issue":"Pt 3","key":"1348_CR39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/eye.1990.70","volume":"4","author":"CN McGhee","year":"1990","unstructured":"McGhee CN, Watson DG, Midgley JM, Noble MJ, Dutton GN, Fern AI. Penetration of synthetic corticosteroids into human aqueous humour. Eye (Lond). 1990;4(Pt 3):526\u201330. https:\/\/doi.org\/10.1038\/eye.1990.70.","journal-title":"Eye (Lond)"},{"key":"1348_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CN McGhee","year":"2002","unstructured":"McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25:33\u201355. https:\/\/doi.org\/10.2165\/00002018-200225010-00004.","journal-title":"Drug Saf"},{"key":"1348_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1358\/dot.2011.47.5.1590791","volume":"47","author":"L Mulki","year":"2011","unstructured":"Mulki L, Foster CS. Difluprednate for inflammatory eye disorders. Drugs Today (Barc). 2011;47:327\u201333. https:\/\/doi.org\/10.1358\/dot.2011.47.5.1590791.","journal-title":"Drugs Today (Barc)"},{"key":"1348_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2147\/opth.s4460","volume":"3","author":"KN Jamal","year":"2009","unstructured":"Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381\u201390. https:\/\/doi.org\/10.2147\/opth.s4460.","journal-title":"Clin Ophthalmol"},{"key":"1348_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00061198-199808000-00009","volume":"7","author":"GD Novack","year":"1998","unstructured":"Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7:266\u20139.","journal-title":"J Glaucoma"},{"key":"1348_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5114\/ko.2017.76217","volume":"119","author":"M \u0141azicka-Ga\u0142ecka","year":"2017","unstructured":"\u0141azicka-Ga\u0142ecka M, Ga\u0142ecki T, Szaflik JP. Safety and efficacy of loteprednol etabonate in treatment of ocular inflammatory diseases. Klinika Oczna\/Acta Ophthalmologica Polonica. 2017;119:239\u201344. https:\/\/doi.org\/10.5114\/ko.2017.76217.","journal-title":"Klinika Oczna\/Acta Ophthalmologica Polonica"},{"key":"1348_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2007.132621","volume":"92","author":"CE Pavesio","year":"2008","unstructured":"Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92:455\u20139. https:\/\/doi.org\/10.1136\/bjo.2007.132621.","journal-title":"Br J Ophthalmol"},{"key":"1348_CR46","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s210597","author":"R Fong","year":"2019","unstructured":"Fong R, Cavet ME, DeCory HH, Vittitow JL. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies. Clin Ophthalmol. 2019. https:\/\/doi.org\/10.2147\/opth.s210597.","journal-title":"Clin Ophthalmol"},{"key":"1348_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/sj.eye.6701895","volume":"20","author":"JP Kersey","year":"2006","unstructured":"Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006;20:407\u201316. https:\/\/doi.org\/10.1038\/sj.eye.6701895.","journal-title":"Eye (Lond)"},{"key":"1348_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/jps.2600790215","volume":"79","author":"JB Richman","year":"1990","unstructured":"Richman JB, Tang-Liu DD. A corneal perfusion device for estimating ocular bioavailability in vitro. J Pharm Sci. 1990;79:153\u20137. https:\/\/doi.org\/10.1002\/jps.2600790215.","journal-title":"J Pharm Sci"},{"key":"1348_CR49","doi-asserted-by":"crossref","unstructured":"Wallsh J, Sharareh B, Gallemore R. Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy. Clin Ophthalmol 2016, 947\u2013954.","DOI":"10.2147\/OPTH.S105412"},{"key":"1348_CR50","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1111\/aos.13152","volume":"95","author":"S Rezar-Dreindl","year":"2017","unstructured":"Rezar-Dreindl S, Eibenberger K, Pollreisz A, B\u00fchl W, Georgopoulos M, Krall C, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol. 2017;95:e119\u201327.","journal-title":"Acta Ophthalmol"},{"key":"1348_CR51","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jamaophthalmol.2017.5316","volume":"136","author":"MR Starr","year":"2018","unstructured":"Starr MR, Maguire LJ, Salom\u00e3o DR. Bilateral corneal deposits 1 week after starting oral prednisone therapy. JAMA Ophthalmol. 2018;136:591\u20132.","journal-title":"JAMA Ophthalmol"},{"key":"1348_CR52","doi-asserted-by":"crossref","unstructured":"Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: an update. Clin Ophthalmol 2011, 811\u2013816.","DOI":"10.2147\/OPTH.S6541"},{"key":"1348_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/jop.2010.0106","volume":"27","author":"T Tajika","year":"2011","unstructured":"Tajika T, Waki M, Tsuzuki M, Kida T, Sakaki H. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. J Ocul Pharmacol Ther. 2011;27:29\u201334.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1348_CR54","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/09273948.2024.2423869","volume":"33","author":"R Amer","year":"2025","unstructured":"Amer R, Pillar S. Review on the use of difluprednate in inflammatory eye disorders: the topical steroid that goes the distance. Ocul Immunol Inflamm. 2025;33:670\u201382. https:\/\/doi.org\/10.1080\/09273948.2024.2423869.","journal-title":"Ocul Immunol Inflamm"},{"key":"1348_CR55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0002-9394(03)00326-X","volume":"136","author":"AM Avunduk","year":"2003","unstructured":"Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;136:593\u2013602.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2005.09.033","volume":"113","author":"HK Lee","year":"2006","unstructured":"Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006;113:198\u2013205. https:\/\/doi.org\/10.1016\/j.ophtha.2005.09.033.","journal-title":"Ophthalmology"},{"key":"1348_CR57","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","volume":"138","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444\u201357.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","volume":"123","author":"J Pinto-Fraga","year":"2016","unstructured":"Pinto-Fraga J, L\u00f3pez-Miguel A, Gonz\u00e1lez-Garc\u00eda MJ, Fern\u00e1ndez I, L\u00f3pez-de-la-Rosa A, Enr\u00edquez-de-Salamanca A, et al. Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial. Ophthalmology. 2016;123:141\u201353.","journal-title":"Ophthalmology"},{"key":"1348_CR59","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14728214.2021.2011858","volume":"26","author":"L Mason","year":"2021","unstructured":"Mason L, Jafri S, Dortonne I, Sheppard JD Jr. Emerging therapies for dry eye disease. Expert Opin Emerg Drugs. 2021;26:401\u201313.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1348_CR60","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276\u201383.","journal-title":"Ocul Surf"},{"key":"1348_CR61","first-page":"1114","volume":"105","author":"CA McCarty","year":"1998","unstructured":"McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne. Aust Ophthalmol. 1998;105:1114\u20139.","journal-title":"Aust Ophthalmol"},{"key":"1348_CR62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","volume":"136","author":"DA Schaumberg","year":"2003","unstructured":"Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318\u201326.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR63","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","volume":"118","author":"SE Moss","year":"2000","unstructured":"Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264\u20138.","journal-title":"Arch Ophthalmol"},{"key":"1348_CR64","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0161-6420(03)00262-8","volume":"110","author":"P-Y Lin","year":"2003","unstructured":"Lin P-Y, Tsai S-Y, Cheng C-Y, Liu J-H, Chou P, Hsu W-M. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2003;110:1096\u2013101.","journal-title":"Ophthalmology"},{"key":"1348_CR65","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/opth.S16832","volume":"5","author":"TL Comstock","year":"2011","unstructured":"Comstock TL, Paterno MR, Singh A, Erb T, Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011;5:177\u201386. https:\/\/doi.org\/10.2147\/opth.S16832.","journal-title":"Clin Ophthalmol"},{"key":"1348_CR66","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/bmt.2012.56","volume":"47","author":"R Jacobs","year":"2012","unstructured":"Jacobs R, Tran U, Chen H, Kassim A, Engelhardt B, Greer J, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant. 2012;47:1470\u20133.","journal-title":"Bone Marrow Transplant"},{"key":"1348_CR67","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s004170100313","volume":"239","author":"C Cursiefen","year":"2001","unstructured":"Cursiefen C, Wenkel H, Martus P, Langenbucher A, Nguyen NX, Seitz B, et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2001;239:514\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1348_CR68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1590\/s0004-27492008000700017","volume":"71","author":"CS de Paiva","year":"2008","unstructured":"de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol. 2008;71:89\u201395. https:\/\/doi.org\/10.1590\/s0004-27492008000700017.","journal-title":"Arq Bras Oftalmol"},{"key":"1348_CR69","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12325-019-01137-8","volume":"37","author":"M Kallab","year":"2020","unstructured":"Kallab M, Szegedi S, Hommer N, Stegmann H, Kaya S, Werkmeister RM, et al. Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial. Adv Ther. 2020;37:329\u201341.","journal-title":"Adv Ther"},{"key":"1348_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30. https:\/\/doi.org\/10.1186\/1710-1492-9-30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1348_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14679","author":"EH Baker","year":"2020","unstructured":"Baker EH. Is there a safe and effective way to wean patients off long-term glucocorticoids? Br J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bcp.14679.","journal-title":"Br J Clin Pharmacol"},{"key":"1348_CR72","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/ijem.ijem_410_23","volume":"28","author":"G Priya","year":"2024","unstructured":"Priya G, Laway BA, Ayyagari M, Gupta M, Bhat GHK, Dutta D. The glucocorticoid taper: a primer for the clinicians. Indian J Endocrinol Metab. 2024;28:350\u201362. https:\/\/doi.org\/10.4103\/ijem.ijem_410_23.","journal-title":"Indian J Endocrinol Metab"},{"key":"1348_CR73","first-page":"205","volume":"99","author":"AJ Flach","year":"2001","unstructured":"Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans Am Ophthalmol Soc. 2001;99:205\u201310.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1348_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.815075","author":"J Ling","year":"2022","unstructured":"Ling J, Chan BC-L, Tsang MS-M, Gao X, Leung PC, Lam CW-K, et al. Current advances in mechanisms and treatment of dry eye disease: toward anti-inflammatory and immunomodulatory therapy and traditional Chinese medicine. Front Med Lausanne. 2022. https:\/\/doi.org\/10.3389\/fmed.2021.815075.","journal-title":"Front Med Lausanne"},{"key":"1348_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2019.07.001","volume":"65","author":"B Rigas","year":"2020","unstructured":"Rigas B, Huang W, Honkanen R. NSAID-induced corneal melt: clinical importance, pathogenesis, and risk mitigation. Surv Ophthalmol. 2020;65:1\u201311. https:\/\/doi.org\/10.1016\/j.survophthal.2019.07.001.","journal-title":"Surv Ophthalmol"},{"key":"1348_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010051.pub2","volume":"9","author":"CS de Paiva","year":"2019","unstructured":"de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019;9:Cd010051. https:\/\/doi.org\/10.1002\/14651858.CD010051.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1348_CR77","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","volume":"130","author":"W Stevenson","year":"2012","unstructured":"Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90\u2013100. https:\/\/doi.org\/10.1001\/archophthalmol.2011.364.","journal-title":"Arch Ophthalmol"},{"key":"1348_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.882803","volume":"13","author":"D Gao","year":"2022","unstructured":"Gao D, Da Z, Yang K, Shi Y. Comparison of seven cyclosporine A formulations for dry eye disease: a systematic review and network meta-analysis. Front Pharmacol. 2022;13:882803. https:\/\/doi.org\/10.3389\/fphar.2022.882803.","journal-title":"Front Pharmacol"},{"key":"1348_CR79","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","volume":"147","author":"EC Kim","year":"2009","unstructured":"Kim EC, Choi J-S, Joo C-K. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147:206-213. e203.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR80","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/s0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631\u20139. https:\/\/doi.org\/10.1016\/s0161-6420(99)00176-1.","journal-title":"Ophthalmology"},{"key":"1348_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2025.2512759","author":"MB Doctor","year":"2025","unstructured":"Doctor MB, Kate A, Tallapelly HG, Basu S. The role of topical cyclosporine A in ocular surface inflammatory disorders. Semin Ophthalmol. 2025. https:\/\/doi.org\/10.1080\/08820538.2025.2512759.","journal-title":"Semin Ophthalmol"},{"key":"1348_CR82","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/ICO.0b013e3181a16472","volume":"28","author":"MH Dastjerdi","year":"2009","unstructured":"Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28:1091\u20136.","journal-title":"Cornea"},{"key":"1348_CR83","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/jop.2015.0078","volume":"32","author":"AI Gire","year":"2016","unstructured":"Gire AI, Karakus S, Ingrodi SM, Akpek EK. Frequent dosing of topical cyclosporine A for severe ocular surface disease. J Ocul Pharmacol Ther. 2016;32:150\u20134.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1348_CR84","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/s0161-6420(00)00035-x","volume":"107","author":"D Stevenson","year":"2000","unstructured":"Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology. 2000;107:967\u201374. https:\/\/doi.org\/10.1016\/s0161-6420(00)00035-x.","journal-title":"Ophthalmology"},{"key":"1348_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04173-x","volume":"25","author":"D Jee","year":"2025","unstructured":"Jee D, Han SY, Kim HS, Kim EC. Comparison of effects of cyclosporine 0.05% and 0.1% in dry eye with Sj\u00f6gren\u2019s syndrome. BMC Ophthalmol. 2025;25:369. https:\/\/doi.org\/10.1186\/s12886-025-04173-x.","journal-title":"BMC Ophthalmol"},{"key":"1348_CR86","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/jop.2010.0085","volume":"27","author":"JD Sheppard","year":"2011","unstructured":"Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther. 2011;27:23\u20137. https:\/\/doi.org\/10.1089\/jop.2010.0085.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1348_CR87","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.sjopt.2018.06.001","volume":"32","author":"TM Othman","year":"2018","unstructured":"Othman TM, Mousa A, Gikandi PW, AbdelMabod M, Abdelrahman AM. Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease. Saudi J Ophthalmol. 2018;32:217\u201321.","journal-title":"Saudi J Ophthalmol"},{"key":"1348_CR88","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","volume":"126","author":"DL Wirta","year":"2019","unstructured":"Wirta DL, Torkildsen GL, Moreira HR, Lonsdale JD, Ciolino JB, Jentsch G, et al. A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. 2019;126:792\u2013800. https:\/\/doi.org\/10.1016\/j.ophtha.2019.01.024.","journal-title":"Ophthalmology"},{"key":"1348_CR89","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jfo.2017.09.005","volume":"41","author":"F Rouimi","year":"2018","unstructured":"Rouimi F, Bouillot A, Baudouin C, Labb\u00e9 A. Topical cyclosporine A and risk of ocular surface neoplasia. J Fr Ophtalmol. 2018;41:122\u20138. https:\/\/doi.org\/10.1016\/j.jfo.2017.09.005.","journal-title":"J Fr Ophtalmol"},{"key":"1348_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-017-0072-z","volume":"4","author":"SS Shoughy","year":"2017","unstructured":"Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis. 2017;4:7.","journal-title":"Eye Vis"},{"key":"1348_CR91","first-page":"805","volume":"59","author":"S Liu","year":"2023","unstructured":"Liu S, Zhao Y, Ma J, Shen Z, Hu B, Peng R, et al. Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease. [Zhonghua yan ke za Zhi]. Chin J Ophthalmol. 2023;59:805\u201313.","journal-title":"Chin J Ophthalmol"},{"key":"1348_CR92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/1120672121992680","volume":"32","author":"P Moawad","year":"2022","unstructured":"Moawad P, Shamma R, Hassanein D, Ragab G, El Zawahry O. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome. Eur J Ophthalmol. 2022;32:673\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"1348_CR93","volume":"10","author":"RK Barot","year":"2016","unstructured":"Barot RK, Shitole SC, Bhagat N, Patil D, Sawant P, Patil K. Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases. J Clin Diagn Res. 2016;10:NC05.","journal-title":"J Clin Diagn Res"},{"key":"1348_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838168","author":"X Chen","year":"2022","unstructured":"Chen X, Wu J, Lin X, Wu X, Yu X, Wang B, et al. Tacrolimus loaded cationic liposomes for dry eye treatment. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.838168.","journal-title":"Front Pharmacol"},{"key":"1348_CR95","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.921301","volume":"21","author":"QS Dirar","year":"2020","unstructured":"Dirar QS, Musalem HM, Al-Hazzaa SA, Al Zoba AA, Almalki AA. Effect of pegylated interferon and mitomycin C on ocular surface squamous neoplasia in xeroderma pigmentosum: a case series. Am J Case Rep. 2020;21:e921301-921301.","journal-title":"Am J Case Rep"},{"key":"1348_CR96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000448220","volume":"3","author":"A Shah","year":"2017","unstructured":"Shah A, Espana EM, Singh AD. Ocular surface squamous neoplasia associated with atopic keratoconjunctivitis. Ocul Oncol Pathol. 2017;3:22\u20137. https:\/\/doi.org\/10.1159\/000448220.","journal-title":"Ocul Oncol Pathol"},{"key":"1348_CR97","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/ICO.0b013e31813e0bed","volume":"26","author":"JA Pournaras","year":"2007","unstructured":"Pournaras JA, Chamot L, Uffer S, Zografos L. Conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation. Cornea. 2007;26:1261\u20132. https:\/\/doi.org\/10.1097\/ICO.0b013e31813e0bed.","journal-title":"Cornea"},{"key":"1348_CR98","unstructured":"LEO Pharma A\/S. Protopic\u00ae (tacrolimus) Ointment 0.03% and 0.1%. Summary of Product Characteristics (SmPC) (EU Product Information). Available online: Accessed 5 Jan 2026."},{"key":"1348_CR99","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3126\/nepjoph.v11i2.27825","volume":"11","author":"E Shrestha","year":"2019","unstructured":"Shrestha E, Banstola L, Maharjan IM, Gurung B, Gurung H, Adhikari HB, et al. Assessing profile and treatment outcome in patients of ocular surface squamous neoplasia (OSSN). Nepal J Ophthalmol. 2019;11:181\u20138.","journal-title":"Nepal J Ophthalmol"},{"key":"1348_CR100","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/jop.2016.0105","volume":"33","author":"SC Pflugfelder","year":"2017","unstructured":"Pflugfelder SC, Stern M, Zhang S, Shojaei A. LFA-1\/ICAM-1 interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33:5\u201312.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1348_CR101","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40265-016-0681-1","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM. Lifitegrast ophthalmic solution 5%: a review in dry eye disease. Drugs. 2017;77:201\u20138.","journal-title":"Drugs"},{"key":"1348_CR102","doi-asserted-by":"publisher","first-page":"49","DOI":"10.18433\/jpps29895","volume":"22","author":"CC Chan","year":"2019","unstructured":"Chan CC, Prokopich CL. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: overview of clinical trial program. J Pharm Pharm Sci. 2019;22:49\u201356.","journal-title":"J Pharm Pharm Sci"},{"key":"1348_CR103","doi-asserted-by":"publisher","DOI":"10.1177\/2515841419870366","volume":"11","author":"SL Haber","year":"2019","unstructured":"Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Therapeutic Adv Ophthalmol. 2019;11:2515841419870366.","journal-title":"Therapeutic Adv Ophthalmol"},{"key":"1348_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11175014","volume":"11","author":"J-X Li","year":"2022","unstructured":"Li J-X, Tsai Y-Y, Lai C-T, Li Y-L, Wu Y-H, Chiang C-C. Lifitegrast ophthalmic solution 5% is a safe and efficient eyedrop for dry eye disease: a systematic review and meta-analysis. J Clin Med. 2022;11:5014.","journal-title":"J Clin Med"},{"key":"1348_CR105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","volume":"124","author":"EJ Holland","year":"2017","unstructured":"Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124:53\u201360.","journal-title":"Ophthalmology"},{"key":"1348_CR106","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/ICL.0000000000000601","volume":"46","author":"AY Tong","year":"2020","unstructured":"Tong AY, Passi SF, Gupta PK. Clinical outcomes of lifitegrast 5% ophthalmic solution in the treatment of dry eye disease. Eye Contact Lens: Sci Clin Pract. 2020;46:S20\u20134.","journal-title":"Eye Contact Lens: Sci Clin Pract"},{"key":"1348_CR107","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/ico.0000000000000051","volume":"33","author":"B Sobolewska","year":"2014","unstructured":"Sobolewska B, Doycheva D, Deuter C, Pfeffer I, Schaller M, Zierhut M. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33:257\u201360. https:\/\/doi.org\/10.1097\/ico.0000000000000051.","journal-title":"Cornea"},{"key":"1348_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013697.pub2","author":"N Onghanseng","year":"2021","unstructured":"Onghanseng N, Ng S, Halim MS, Nguyen Q. Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev. 2021. https:\/\/doi.org\/10.1002\/14651858.CD013697.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1348_CR109","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","volume":"52","author":"G Geerling","year":"2011","unstructured":"Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O\u2019Brien T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050\u201364. https:\/\/doi.org\/10.1167\/iovs.10-6997g.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1348_CR110","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00417-019-04322-1","volume":"257","author":"V Satitpitakul","year":"2019","unstructured":"Satitpitakul V, Ratanawongphaibul K, Kasetsuwan N, Reinprayoon U. Efficacy of azithromycin 1.5% eyedrops vs oral doxycycline in meibomian gland dysfunction: a randomized trial. Graefes Arch Clin Exp Ophthalmol. 2019;257:1289\u201394. https:\/\/doi.org\/10.1007\/s00417-019-04322-1.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1348_CR111","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamaophthalmol.2023.0302","volume":"141","author":"P Upaphong","year":"2023","unstructured":"Upaphong P, Tangmonkongvoragul C, Phinyo P. Pulsed oral azithromycin vs 6-week oral doxycycline for moderate to severe Meibomian Gland Dysfunction: a randomized clinical trial. JAMA Ophthalmol. 2023;141:423\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.0302.","journal-title":"JAMA Ophthalmol"},{"key":"1348_CR112","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","volume":"19","author":"SE Yoo","year":"2005","unstructured":"Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19:258\u201363. https:\/\/doi.org\/10.3341\/kjo.2005.19.4.258.","journal-title":"Korean J Ophthalmol"},{"key":"1348_CR113","doi-asserted-by":"publisher","DOI":"10.1177\/2515841418783622","volume":"10","author":"KA Kagkelaris","year":"2018","unstructured":"Kagkelaris KA, Makri OE, Georgakopoulos CD, Panayiotakopoulos GD. An eye for azithromycin: review of the literature. Ther Adv Ophthalmol. 2018;10:2515841418783622. https:\/\/doi.org\/10.1177\/2515841418783622.","journal-title":"Ther Adv Ophthalmol"},{"key":"1348_CR114","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bjophthalmol-2014-305410","volume":"99","author":"MB Kashkouli","year":"2015","unstructured":"Kashkouli MB, Fazel AJ, Kiavash V, Nojomi M, Ghiasian L. Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial. Br J Ophthalmol. 2015;99:199\u2013204. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305410.","journal-title":"Br J Ophthalmol"},{"key":"1348_CR115","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/aos.15681","volume":"102","author":"D Ben Ephraim Noyman","year":"2024","unstructured":"Ben Ephraim Noyman D, Chan CC, Mimouni M, Safir M. Systemic antibiotic treatment for meibomian gland dysfunction-a systematic review and meta-analysis. Acta Ophthalmol. 2024;102:e1\u201310. https:\/\/doi.org\/10.1111\/aos.15681.","journal-title":"Acta Ophthalmol"},{"key":"1348_CR116","first-page":"336","volume":"106","author":"MS Macsai","year":"2008","unstructured":"Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336\u201356.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1348_CR117","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","volume":"378","author":"PA Asbell","year":"2018","unstructured":"Asbell PA, Maguire MG, Pistilli M, Ying GS, Szczotka-Flynn LB, Hardten DR, et al. N-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018;378:1681\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1709691.","journal-title":"N Engl J Med"},{"key":"1348_CR118","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/bjophthalmol-2012-302568","volume":"97","author":"P Aragona","year":"2013","unstructured":"Aragona P, Rolando M. Towards a dynamic customised therapy for ocular surface dysfunctions. Br J Ophthalmol. 2013;97:955\u201360. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302568.","journal-title":"Br J Ophthalmol"},{"key":"1348_CR119","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s40123-024-01003-z","volume":"13","author":"P Aragona","year":"2024","unstructured":"Aragona P, Giannaccare G, Dammino E, D\u2019Esposito F, Genovese P, Postorino EI, et al. Observational clinical investigation evaluating an ophthalmic solution containing Xanthan Gum and low concentration Desonide Phosphate in dry eye disease treatment. Ophthalmol Ther. 2024;13:2559\u201373. https:\/\/doi.org\/10.1007\/s40123-024-01003-z.","journal-title":"Ophthalmol Ther"},{"key":"1348_CR120","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40123-023-00833-7","volume":"13","author":"P Fogagnolo","year":"2024","unstructured":"Fogagnolo P, Giannaccare G, Mencucci R, Villani E, Orfeo V, Aragona P. Effectiveness of a new active tear substitute containing 0.2% hyaluronic acid and 0.001% hydrocortisone on signs and symptoms of dry eye disease by means of low- and high-tech assessments. Ophthalmol Ther. 2024;13:251\u201366. https:\/\/doi.org\/10.1007\/s40123-023-00833-7.","journal-title":"Ophthalmol Ther"},{"key":"1348_CR121","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2025.2485236","author":"C Rodriguez-Pomar","year":"2025","unstructured":"Rodriguez-Pomar C, Carpena-Torres C, Serramito M, Perez-de-Lara MJ, Martinez-Aguila A, Martin-Gil A, et al. Decreased inflammatory biomarkers after using artificial tears with Aloe vera and hypromellose for dry eye. Clin Exp Optom. 2025. https:\/\/doi.org\/10.1080\/08164622.2025.2485236.","journal-title":"Clin Exp Optom"},{"key":"1348_CR122","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/opo.12280","volume":"36","author":"LE Downie","year":"2016","unstructured":"Downie LE, Rumney N, Gad A, Keller PR, Purslow C, Vingrys AJ. Comparing self-reported optometric dry eye clinical practices in Australia and the United Kingdom: is there scope for practice improvement? Ophthalmic Physiol Opt. 2016;36:140\u201351.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1348_CR123","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/ICL.0000000000000020","volume":"40","author":"JF Williamson","year":"2014","unstructured":"Williamson JF, Huynh K, Weaver MA, Davis RM. Perceptions of dry eye disease management in current clinical practice. Eye Contact Lens: Sci Clin Pract. 2014;40:111\u20135.","journal-title":"Eye Contact Lens: Sci Clin Pract"},{"key":"1348_CR124","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/opo.12349","volume":"37","author":"AL Xue","year":"2017","unstructured":"Xue AL, Downie LE, Ormonde SE, Craig JP. A comparison of the self\u2010reported dry eye practices of New Zealand optometrists and ophthalmologists. Ophthalmic Physiol Opt. 2017;37:191\u2013201.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1348_CR125","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/OPX.0000000000000087","volume":"90","author":"LE Downie","year":"2013","unstructured":"Downie LE, Keller PR, Vingrys AJ. An evidence-based analysis of Australian optometrists\u2019 dry eye practices. Optom Vis Sci. 2013;90:1385\u201395.","journal-title":"Optom Vis Sci"},{"key":"1348_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.039","author":"L Jones","year":"2025","unstructured":"Jones L, Craig JP, Markoulli M, Karpecki P, Akpek EK, Basu S, et al. TFOS DEWS III management and therapy report. Am J Ophthalmol. 2025. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.039.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR127","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jtos.2024.12.008","volume":"36","author":"JS Wolffsohn","year":"2025","unstructured":"Wolffsohn JS, Semp DA, Dutta D, Jones L, Craig JP. Clinical practice patterns in the management of dry eye disease: a TFOS international survey 2023-24. Ocul Surf. 2025;36:164\u201372. https:\/\/doi.org\/10.1016\/j.jtos.2024.12.008.","journal-title":"Ocul Surf"},{"key":"1348_CR128","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/07853890.2022.2157477","volume":"55","author":"J Sheppard","year":"2023","unstructured":"Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55:241\u201352.","journal-title":"Ann Med"},{"key":"1348_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030990","volume":"15","author":"H Mondal","year":"2023","unstructured":"Mondal H, Kim H-J, Mohanto N, Jee J-P. A review on dry eye disease treatment: recent progress, diagnostics, and future perspectives. Pharmaceutics. 2023;15:990.","journal-title":"Pharmaceutics"},{"key":"1348_CR130","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clae.2016.04.002","volume":"39","author":"E Bitton","year":"2016","unstructured":"Bitton E, Lacroix Z, L\u00e9ger S. In-vivo heat retention comparison of eyelid warming masks. Contact Lens Anterior Eye. 2016;39:311\u20135.","journal-title":"Contact Lens Anterior Eye"},{"key":"1348_CR131","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jtos.2019.02.005","volume":"17","author":"D Borchman","year":"2019","unstructured":"Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf. 2019;17:360\u20134.","journal-title":"Ocul Surf"},{"key":"1348_CR132","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/ICO.0000000000002997","volume":"42","author":"G Giannaccare","year":"2023","unstructured":"Giannaccare G, Pellegrini M, Scalzo GC, Borselli M, Ceravolo D, Scorcia V. Low-level light therapy versus intense pulsed light for the treatment of meibomian gland dysfunction: preliminary results from a prospective randomized comparative study. Cornea. 2023;42:141\u20134.","journal-title":"Cornea"},{"key":"1348_CR133","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jtos.2020.01.003","volume":"18","author":"AL Xue","year":"2020","unstructured":"Xue AL, Wang MT, Ormonde SE, Craig JP. Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction. Ocul Surf. 2020;18:286\u201397.","journal-title":"Ocul Surf"},{"key":"1348_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0122-z","volume":"15","author":"A Sy","year":"2015","unstructured":"Sy A, O\u2019Brien KS, Liu MP, Cuddapah PA, Acharya NR, Lietman TM, et al. Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED). BMC Ophthalmol. 2015;15:133.","journal-title":"BMC Ophthalmol"},{"key":"1348_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-025-00462-0","volume":"15","author":"W Qian","year":"2025","unstructured":"Qian W, Wu Y, Liu X, Liu Y, Li M, Zhao T, et al. Efficacy of 0.05% cyclosporine A on tear inflammatory cytokines and goblet cell function after corneal refractive surgery. J Ophthalmic Inflamm Infect. 2025;15:36. https:\/\/doi.org\/10.1186\/s12348-025-00462-0.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1348_CR136","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","volume":"74","author":"B Qin","year":"2015","unstructured":"Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:1983\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1348_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102809","author":"E Michaelov","year":"2022","unstructured":"Michaelov E, McKenna C, Ibrahim P, Nayeni M, Dang A, Mather R. Sj\u00f6gren\u2019s syndrome associated dry eye: impact on daily living and adherence to therapy. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11102809.","journal-title":"J Clin Med"},{"key":"1348_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2011.06.007","volume":"141","author":"R Jonsson","year":"2011","unstructured":"Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S. The complexity of Sj\u00f6gren\u2019s syndrome: novel aspects on pathogenesis. Immunol Lett. 2011;141:1\u20139.","journal-title":"Immunol Lett"},{"key":"1348_CR139","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0161-6420(90)32478-8","volume":"97","author":"SC Pflugfelder","year":"1990","unstructured":"Pflugfelder SC, Huang AJ, Feuer W, Chuchovski PT, Pereira IC, Tseng SC. Conjunctival cytologiec features of primary Sj\u00f6gren\u2019s syndrome. Ophthalmology. 1990;97:985\u201391.","journal-title":"Ophthalmology"},{"key":"1348_CR140","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1542-0124(12)70187-8","volume":"7","author":"ME Johnson","year":"2009","unstructured":"Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf. 2009;7:199\u2013211.","journal-title":"Ocul Surf"},{"key":"1348_CR141","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","volume":"143","author":"B Miljanovi\u0107","year":"2007","unstructured":"Miljanovi\u0107 B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409-415. e402.","journal-title":"Am J Ophthalmol"},{"key":"1348_CR142","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40271-014-0060-5","volume":"7","author":"F Ahmed","year":"2014","unstructured":"Ahmed F, Burt J, Roland M. Measuring patient experience: concepts and methods. Patient Patient-Centered Outcomes Res. 2014;7:235\u201341.","journal-title":"Patient Patient-Centered Outcomes Res"},{"key":"1348_CR143","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40265-024-02031-6","volume":"84","author":"D Vald\u00e9s-Arias","year":"2024","unstructured":"Vald\u00e9s-Arias D, Locatelli EVT, Sepulveda-Beltran PA, Mangwani-Mordani S, Navia JC, Galor A. Recent United States developments in the pharmacological treatment of dry eye disease. Drugs. 2024;84:549\u201363. https:\/\/doi.org\/10.1007\/s40265-024-02031-6.","journal-title":"Drugs"},{"key":"1348_CR144","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/aci.0000000000001017","volume":"24","author":"A Flts","year":"2024","unstructured":"Flts A, Medina R, Akpek EK. The evolution of cyclosporine treatments for treatment of ocular surface diseases. Curr Opin Allergy Clin Immunol. 2024;24:360\u20137. https:\/\/doi.org\/10.1097\/aci.0000000000001017.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1348_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/biom13050724","author":"H Shan","year":"2023","unstructured":"Shan H, Liu W, Li Y, Pang K. The autoimmune rheumatic disease related dry eye and its association with retinopathy. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13050724.","journal-title":"Biomolecules"},{"key":"1348_CR146","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50276","volume":"15","author":"A K\u0131l\u0131\u00e7\u00e7\u0131o\u011flu","year":"2023","unstructured":"K\u0131l\u0131\u00e7\u00e7\u0131o\u011flu A, Oncel D, Celebi ARC. Autoimmune disease-related dry eye diseases and their placement under the revised classification systems: an update. Cureus. 2023;15:e50276. https:\/\/doi.org\/10.7759\/cureus.50276.","journal-title":"Cureus"},{"key":"1348_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102118","author":"V Promelle","year":"2021","unstructured":"Promelle V, Goeb V, Gueudry J. Rheumatoid arthritis associated episcleritis and scleritis: an update on treatment perspectives. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10102118.","journal-title":"J Clin Med"},{"key":"1348_CR148","doi-asserted-by":"publisher","DOI":"10.1080\/2331205X.2016.1243771","author":"N Lamba","year":"2016","unstructured":"Lamba N, Lee S, Chaudhry H, Foster C. A review of the ocular manifestations of rheumatoid arthritis. Cogent Med. 2016. https:\/\/doi.org\/10.1080\/2331205X.2016.1243771.","journal-title":"Cogent Med"},{"key":"1348_CR149","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum. 2008;58:15\u201325.","journal-title":"Arthritis Rheum"},{"key":"1348_CR150","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10238-017-0479-9","volume":"18","author":"R Dammacco","year":"2018","unstructured":"Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2018;18:135\u201349.","journal-title":"Clin Exp Med"},{"key":"1348_CR151","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00296-011-2296-x","volume":"33","author":"RR El-Shereef","year":"2013","unstructured":"El-Shereef RR, Mohamed AS, Hamdy L. Ocular manifestation of systemic lupus erythematosus. Rheumatol Int. 2013;33:1637\u201342.","journal-title":"Rheumatol Int"},{"key":"1348_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20053776","author":"CH Tseng","year":"2023","unstructured":"Tseng CH, Tai YH, Hong CT, Dai YX, Chen TJ, Cherng YG, et al. Systemic lupus erythematosus and risk of dry eye disease and corneal surface damage: a population-based cohort study. Int J Environ Res Public Health. 2023. https:\/\/doi.org\/10.3390\/ijerph20053776.","journal-title":"Int J Environ Res Public Health"},{"key":"1348_CR153","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.4103\/IJO.IJO_3386_22","volume":"71","author":"SB Murugan","year":"2023","unstructured":"Murugan SB, Somanath A. Commentary: systemic lupus erythematosus retinopathy: eye or multisystem involvement? Indian J Ophthalmol. 2023;71:1994\u20135. https:\/\/doi.org\/10.4103\/IJO.IJO_3386_22.","journal-title":"Indian J Ophthalmol"},{"key":"1348_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041047","author":"M Musa","year":"2024","unstructured":"Musa M, Chukwuyem E, Ojo OM, Topah EK, Spadea L, Salati C, et al. Unveiling ocular manifestations in systemic Lupus Erythematosus. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13041047.","journal-title":"J Clin Med"},{"key":"1348_CR155","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/mi.2009.5","volume":"2","author":"C De Paiva","year":"2009","unstructured":"De Paiva C, Chotikavanich S, Pangelinan S, Pitcher J, Fang B, Zheng X, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2:243\u201353.","journal-title":"Mucosal Immunol"},{"key":"1348_CR156","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/mi.2015.53","volume":"9","author":"L Garcia-Posadas","year":"2016","unstructured":"Garcia-Posadas L, Hodges R, Li D, Shatos M, Storr-Paulsen T, Diebold Y, et al. Interaction of IFN-\u03b3 with cholinergic agonists to modulate rat and human goblet cell function. Mucosal Immunol. 2016;9:206\u201317.","journal-title":"Mucosal Immunol"},{"key":"1348_CR157","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S0161-6420(88)33228-8","volume":"95","author":"R Wieczorek","year":"1988","unstructured":"Wieczorek R, Jakobiec FA, Sacks EH, Knowles DM. The immunoarchitecture of the normal human lacrimal gland: relevancy for understanding pathologic conditions. Ophthalmology. 1988;95:100\u20139.","journal-title":"Ophthalmology"},{"key":"1348_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108115","volume":"197","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder SC, Stern ME. Biological functions of tear film. Exp Eye Res. 2020;197:108115. https:\/\/doi.org\/10.1016\/j.exer.2020.108115.","journal-title":"Exp Eye Res"},{"key":"1348_CR159","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue JS, Figueiredo FC, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26:287\u201396. https:\/\/doi.org\/10.5301\/ejo.5000779.","journal-title":"Eur J Ophthalmol"},{"key":"1348_CR160","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40265-017-0834-x","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM. Ciclosporin ophthalmic emulsion 0.1%: a review in severe dry eye disease. Drugs. 2017;77:1909\u201316. https:\/\/doi.org\/10.1007\/s40265-017-0834-x.","journal-title":"Drugs"},{"key":"1348_CR161","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40123-022-00487-x","volume":"11","author":"G Geerling","year":"2022","unstructured":"Geerling G, Hamada S, Trocm\u00e9 S, R\u00e6der S, Chen X, Fassari C, et al. Real-world effectiveness, tolerability and safety of cyclosporine A 0.1% cationic emulsion in severe keratitis and dry eye treatment. Ophthalmol Ther. 2022;11:1101\u201317. https:\/\/doi.org\/10.1007\/s40123-022-00487-x.","journal-title":"Ophthalmol Ther"},{"key":"1348_CR162","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/09273948.2022.2088566","volume":"31","author":"M Labetoulle","year":"2023","unstructured":"Labetoulle M, Leonardi A, Pisella PJ, Baudouin C. Ciclosporin A cationic emulsion 0.1% for the management of dry eye disease: facts that matter for eye-care providers. Ocul Immunol Inflamm. 2023;31:1707\u201315. https:\/\/doi.org\/10.1080\/09273948.2022.2088566.","journal-title":"Ocul Immunol Inflamm"},{"key":"1348_CR163","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","volume":"12","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Nichols KK. Dry eye disease associated with Meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12:1397\u2013418. https:\/\/doi.org\/10.1007\/s40123-023-00669-1.","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01348-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:02:13Z","timestamp":1775138533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01348-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":163,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01348-7","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giuseppe Giannaccare received a publication grant from Santen. Botagoz Issergepova received scientific consultation and lecture fees from Santen. B.I. is a member of the Expert Council on Corneal Pathology of the Kazakhstan Society of Ophthalmologists. Maciej Kozak, Dominika Wr\u00f3bel-Dudzi\u0144ska, Gulnara Begimbayeva Yenbekovna, Camelia Margareta Bogdanici, Iryna Deryapa, Kamila Ku\u0161ev, Zolt\u00e1n Nagy, Ma\u0142gorzata Stawska, Luidmila Troychenko, Robert Rejdak, and Tomasz Chor\u0105giewicz declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Written informed consent to publish the clinical details and any accompanying images was obtained from all patients and all data have been anonymized to protect patient confidentiality.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}